.png)
Concorde Biotech's IPO is going to open for subscription on August 4. Concorde Biotech's IPO will close on August 8. Concorde Biotech's shares will be listed on both NSE and BSE exchanges. All the details related to the IPO offer of Concorde Biotech are given below.
How is the industry performance related to Concord Biotech?
.jpg) |
| Concord Biotech IPO |
What kind of business does Concorde Biotech Company do?
In the intricate realm of pharmaceutical innovation, Concord Biotech emerges as a compelling force. This biopharma marvel orchestrates its prowess in the manufacture of select fermentation-based APIs, navigating the realms of immunosuppressants and oncology with an artistry that mirrors nature's complexity. Amidst its creative symphony, a harmonious interplay of 23 APIs delicately threads through the tapestry of immunosuppressants, oncology, and anti-infectives. But the spotlight doesn't dim here; It brilliantly illuminates 77 approved products elegantly poised for formulations.
How is the industry performance related to Concord Biotech?
Venturing into the grand theater of industry dynamics, Concord Biotech takes center stage in the oncology drug market. A behemoth within therapeutic arenas, this market beholds a staggering sales value, a formidable $42 billion in the year 2022. As we traverse further, the anti-infectives market graces the scene with its own tale of significance, boasting a robust sales value of $32 billion during the same epoch. Meanwhile, the Immunosuppressants market, a vital player in this narrative, claims its throne with a valuation crowned at $16 billion.
What is the size of the Concord Biotech IPO?
This financial spectacle, a manifestation of strategic intent, weaves together an offering of 2.09 crore equity shares, a monetary crescendo soaring up to a majestic Rs 1,551 crore. Notably, this offering basks in the allure of exclusivity; it refrains from birthing any fresh equity issue, making its journey an intriguing dance of existing assets.
Who Are the Key Players Behind the OFS in Concord Biotech's IPO?
Amidst the symphony of transactions, the spotlight falls upon the enigmatic figures within the OFS domain. Here, Helix Investment Holdings Pte Ltd, a protagonist backed by the resolute Quadria Capital, takes center stage. With an air of deliberation, 2.09 crore equity shares gracefully find their way into the realm of offerings, a tale of strategic divestment etched in financial elegance.
What is the price band for the Concord Biotech IPO?
Concord Biotech, the maestro of precision, masterfully anchors its price band at Rs 705-741 per share, inviting investors to engage in a symphony of bids. A minimum of 20 shares entices participation, with the ensuing multiples crafting a symphony of opportunity, casting its allure upon the discerning minds of the investing audience.
How Does Concord Biotech IPO Cater to Different Investor Segments?
Stepping into the amphitheater of structural ingenuity, the Concord Biotech IPO extends an invitation to various segments of the investment landscape. A grand feast awaits, where 50% of the offering finds its resonance with the qualified institutional buyers (QIBs), echoing the call of institutional elegance. A gracious 15% is unveiled for the non-institutional investors (NII), their entry carving a path for diverse participation. As the final stroke of structural brilliance, 35% remains dedicated to the cherished realm of retail investors, celebrating the spirit of individual engagement.
What Impressive Financial Milestones Did Concord Biotech Achieve in 2023?
In the financial theater, where numbers dance in eloquent rhythm, Concord Biotech graces the stage with a performance worthy of applause. As the curtains fall on the year concluding March 2023, a symphony of financial notes unfurls. Revenues, a testament to prowess, resound at a majestic Rs 888 crore, orchestrating a melody of success. Amidst this financial symphony, the profit takes its place, a key soloist with a resounding Rs 240 crore note.
What Noble Objectives Drive Concord Biotech's IPO Proceeds?
Gaze upon the realm of intent, where the objectives of the Concord Biotech IPO emerge with crystal clarity. A strategic waltz unfolds, wherein the company graciously forgoes any claim to the proceeds of the offer. Instead, an altruistic gesture prevails; the sum in its entirety embarks on a journey to honor the selling shareholder, an ode to collaboration and shared aspirations.
Wondering About the Current GMP and Market Sentiment for Concord Biotech?
As whispers of market sentiment flutter through the air, the current GMP of Concord Biotech takes center stage, an enigma cloaked in numbers. According to the sagacious analysts of the market, the present GMP finds its echo at approximately Rs 325 per share in the uncharted territories of the unlisted market. A testament to the allure this performance commands, a number that transcends the ordinary and ventures into the realm of intrigue.
Who Are the Lead Managers Steering Concord Biotech's IPO Success?
Guiding this financial symphony with masterful precision, a trio of book-running lead managers takes the helm. Kotak Mahindra Capital, Jefferies India, and Citigroup join hands in an intricate dance, orchestrating a performance that captivates the senses. Amidst this choreography, Link Intime India emerges as the registrar for this grand spectacle, ensuring that every note, every transaction, is etched into the annals of financial history. The narrative of Concord Biotech's IPO, a story of complexity and diversity, of strategy and emotion, finds its crescendo, a resounding note that lingers in the minds of all who bear witness.
